mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 7, 2012, Pages

  Faustino, Alexandra ^a   Couto, Joana P ^a,b   Pópulo, Helena ^a,b   Rocha, Ana Sofia ^a   Pardal, Fernando ^c   Cameselle Teijeiro, José Manuel ^d   Lopes, José Manuel ^a,b,e   Sobrinho Simões, Manuel ^a,b,e   Soares, Paula ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c HOSPITAL DE BRAGA   (Portugal)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^e HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE LKB1; RAPAMYCIN; SERINE; SMALL INTERFERING RNA; VALINE;

ARTICLE; BRAF GENE; CANCER GENETICS; CANCER GROWTH; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; EXPRESSION VECTOR; GENE; GENE INACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

AMINO ACID SUBSTITUTION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMIC ACID; HEK293 CELLS; HUMANS; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; SERINE; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES; TRANSFECTION; UP-REGULATION; VALINE;

MAMMALIA;

EID: 84863566153     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2748     Document Type: Article

References (40)

1. Guertin DA, Sabatini DM 2005 An expanding role for mTOR in cancer. Trends Mol Med 11:353-361 (Pubitemid 41080576)
2. Wullschleger S, Loewith R, Hall MN 2006 TOR signaling in growth and metabolism. Cell 124:471-484
3. Hay N, Sonenberg N 2004 Upstream and downstream of mTOR. Genes Dev 18:1926-1945 (Pubitemid 39071573)
4. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM 2005 Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101 (Pubitemid 40262113)
5. Hardie DG, Scott JW, Pan DA, Hudson ER 2003 Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 546:113-120 (Pubitemid 36782291)
6. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC 2004 The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101:3329-3335 (Pubitemid 38338195)
7. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, De-Pinho RA, Cantley LC 2004 The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:91-99 (Pubitemid 38903165)
8. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, Cantley LC 2009 Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 33:237-247
9. Esteve-Puig R, Canals F, Colomé N, Merlino G, Recio JA 2009 Uncoupling of the LKB1-AMPKα energy sensor pathway by growth factors and oncogenic BRAF. PLoS One 4:e4771
10. Kondo T, Ezzat S, Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292-306
11. Sobrinho-Simões M, Máximo V, Rocha AS, Trovisco V, Castro P, Preto A, Lima J, Soares P 2008 Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am 37:333-362, viii
12. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RASBRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457 (Pubitemid 36373628)
13. Zhu XL, Zhou XY, Zhu XZ 2005 [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma]. Zhonghua Bing Li Xue Za Zhi 34:270-274
14. Alvarez-Nuñez F, Bussaglia E, Mauricio D, Ybarra J, Vilar M, Lerma E, de Leiva A, Matias-Guiu X 2006 PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 16:17-23 (Pubitemid 43346499)
15. Halachmi N, Halachmi S, Evron E, Cairns P, Okami K, Saji M, Westra WH, Zeiger MA, Jen J, Sidransky D 1998 Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer 23:239-243 (Pubitemid 28465640)
16. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, Gil E, Hinze R, Delbridge L, Lees JA, Mutter GL, Robinson BG, Komminoth P, Dralle H, Eng C 2000 Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156:1693-1700 (Pubitemid 30646707)
17. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D, Xing M 2005 Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90:4688-4693 (Pubitemid 41159359)
18. Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M, Al-Sanea O, Al-Dayel F, Uddin S, Al-Kuraya KS 2008 Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 93:611-618 (Pubitemid 351240838)
19. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J 1994 Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527-532 (Pubitemid 24264918)
20. Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD, Downward J 1996 Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J 15:2442-2451 (Pubitemid 26151184)
21. Miyagi E, Braga-Basaria M, Hardy E, Vasko V, Burman KD, Jhiang S, Saji M, Ringel MD 2004 Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Mol Carcinog 41:98-107 (Pubitemid 39336759)
22. Jung HS, Kim DW, Jo YS, Chung HK, Song JH, Park JS, Park KC, Park SH, Hwang JH, Jo KW, Shong M 2005 Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases. Mol Endocrinol 19:2748-2759 (Pubitemid 41577247)
23. Kim DW, Hwang JH, Suh JM, Kim H, Song JH, Hwang ES, Hwang IY, Park KC, Chung HK, Kim JM, Park J, Hemmings BA, Shong M 2003 RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1. Mol Endocrinol 17:1382-1394 (Pubitemid 36819958)
24. Pópulo H, Soares P, Rocha AS, Silva P, Lopes JM 2010 Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res 20:107-117
25. Pópulo H, Soares P, Faustino A, Rocha AS, Silva P, Azevedo F, Lopes JM 2011 mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment Cell Melanoma Res 24:254-257
26. Meireles AM, Preto A, Rocha AS, Rebocho AP, Máximo V, Pereira-Castro I, Moreira S, Feijão T, Botelho T, Marques R, Trovisco V, Cirnes L, Alves C, Velho S, Soares P, Sobrinho-Simões M 2007 Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid 17:707-715
27. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69:4885-4893
28. Preto A, Gonçalves J, Rebocho AP, Figueiredo J, Meireles AM, Rocha AS, Vasconcelos HM, Seca H, Seruca R, Soares P, Sobrinho-Simões M 2009 Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer 9:387
29. Miyakawa M, Tsushima T, Murakami H, Wakai K, Isozaki O, Takano K 2003 Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocr J 50:77-83 (Pubitemid 36305850)
30. Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V, Miyakawa M, Isozaki O, Murakami H, Tsushima T, Burman KD, De Micco C, Ringel MD 2004 Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 41:161-170 (Pubitemid 38333792)
31. Tamguney T, Stokoe D 2007 New insights into PTEN. J Cell Sci 120:4071-4079
32. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H, Tempst P, Chi SG, Kim HJ, Misteli T, Jiang X, Pandolfi PP 2007 Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128:141-156 (Pubitemid 46048885)
33. Maccario H, Perera NM, Gray A, Downes CP, Leslie NR 2010 Ubiquitination of PTEN (phosphatase and tensin homolog) inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress. J Biol Chem 285:12620-12628
34. Rapa I, Saggiorato E, Giachino D, Palestini N, Orlandi F, Papotti M, Volante M 2011 Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. J Clin Endocrinol Metab 96:2146-2153
35. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW 2009 Dual inhi bition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 94:4107-4112
36. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW 2011 Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res 17:6482-6489
37. Liu D, Xing J, Trink B, Xing M 2010 BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer 127:2965-2973
38. Choi HJ, Kim TY, Chung N, Yim JH, Kim WG, Kim JA, Kim WB, Shong YK 2011 The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside. J Endocrinol 211:79-85
39. Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, Nistal M, Santisteban P 2006 The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer 13:257-269
40. de Souza EC, Padrón AS, Braga WM, de Andrade BM, Vaisman M, Nasciutti LE, Ferreira AC, de Carvalho DP 2010 MTOR downregulates iodide uptake in thyrocytes. J Endocrinol 206:113-120